Does Ivosidenib Interact with Mao Inhibitors?
Ivosidenib and Mao Inhibitors have a major drug interaction according to U.S. FDA drug labeling data. Co-administration increases ivosidenib plasma concentrations and may increase risk of QTc interval prolongation. Reduce TIBSOVO dose to 250 mg once daily if unavoidable. The mechanism involves cyp3a4 inhibition increases ivosidenib exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Ivosidenib Class
- Isocitrate Dehydrogenase 1 Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Ivosidenib and Mao Inhibitors occurs because cyp3a4 inhibition increases ivosidenib exposure. Clinically, this means co-administration increases ivosidenib plasma concentrations and may increase risk of qtc interval prolongation. reduce tibsovo dose to 250 mg once daily if unavoidable. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Ivosidenib and your doctor is considering prescribing Mao Inhibitors (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider